Protein and Skeletal Muscle in Older Twins: Role of the Gut Microbiome

Sarcopenia Clinical Trial

— PROMOTe  

Official title:

Dietary Protein and Skeletal Muscle in Older Twins - Targeting the Gut Microbiome to Overcome Anabolic Resistance: The PROMOTe Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04309292
• Other study ID #: 1234
• Status: Completed
• Phase: N/A
• Start date: April 29, 2021
• Est. completion date: December 20, 2021

Study information

• Verified date: February 2021
• Source: King's College London
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Research Question: Does the gut microbiome contribute to muscle anabolic resistance to protein supplementation in older adults?

Background: Loss of muscle occurs with age and skeletal muscle in older adults can display anabolic resistance to protein in diet. It has been hypothesised that the gut microbiome may play a role in this relationship and therefore could be targeted.

Aim:

This trial aims to test whether modulation of the gut microbiome, in addition to protein supplementation, can improve skeletal muscle function versus protein supplementation alone.

Methods:

Double blinded, randomised, placebo controlled, dietary intervention study. Twin pairs will be randomised to either receive protein supplementation plus placebo or protein supplementation plus a gut microbiome modulator (prebiotic plus probiotic) for 12 weeks. Primary outcome will be muscle function measured using chair-rise time.

Conclusion:

Anabolic resistance warrants further characterisation to guide future therapeutic interventions, especially considering its role in the development of disability, sarcopenia and frailty.

Description:

Research Question: Does the gut microbiome contribute to muscle anabolic resistance to protein supplementation in older adults?

Background: Loss of skeletal muscle mass and strength occurs with increasing age and is associated with loss of function, disability, and the development of sarcopenia and frailty. Dietary protein is essential for skeletal muscle function, but older adults do not respond as well as younger people to protein, so called 'anabolic resistance'. The aetiology and molecular mechanisms for this are not understood, however a number have been proposed. The gut microbiome is known to play a key role in a number of these postulated mechanisms. This has led us to hypothesise that the gut microbiome may mediate anabolic resistance and could represent an exciting new target for ameliorating muscle loss in older adults.

Aim:

This trial aims to test whether modulation of the gut microbiome, in addition to protein supplementation, can improve skeletal muscle function versus protein supplementation alone.

Methods:

Double blinded, randomised, placebo controlled, dietary intervention study. Volunteers will be recruited in twin pairs from TwinsUK cohort, for which extensive baseline data are available. The twin nature of the study allows for close genetic and environmental matching at baseline. Each pair will be randomised to either receive protein supplementation plus placebo or protein supplementation plus a gut microbiome modulator (prebiotic plus probiotic). Intervention period will be 12 weeks. Clinical and biochemical measures will be taken at 0, and 12 weeks, with 2-monthly contact. Gut microbiota composition will be measured, alongside a battery of physical assessments. Primary outcome will be muscle function measured using chair-rise time. The trial will be delivered remotely using video calls, and postal boxes.

Conclusion:

Anabolic resistance warrants further characterisation to guide future therapeutic interventions, especially considering its role in the development of disability, sarcopenia and frailty. Therapeutic options are badly needed, particularly for older adults who cannot undertake exercise programmes.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 71
• Est. completion date: December 20, 2021
• Est. primary completion date: December 20, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 60 Years to 120 Years

Eligibility

Inclusion Criteria:

• Aged >=60 years

• Dietary protein intake of <1.3g/kg/day

• Able to consent

• Able to access video calls on a device such as laptop/tablet

Exclusion Criteria:

• Severe food allergy

• Current or recent antibiotic use (preceding 3 months)

• Currently or recent use of protein or leucine supplements (preceding 3 months)

• Currently or recent use of probiotic or prebiotic food supplements (preceding 3 months)

• Current or prior history of gastrointestinal disease e.g. gastrointestinal cancer, inflammatory bowel disease, bariatric surgery, irritable bowel syndrome

• history of any significant injury or surgery which currently affects physical functioning and ability to undertake chair stand test

• weight loss of =5% of body weight in preceding 6-12 months

• Currently involved in other intervention studies

• Any condition or circumstance likely to interfere with the normal conduct of the study and interpretation of the results, as judged by the investigators As the study population are over 60 years old, it is assumed that there will be no pregnant women who are eligible to take part.

Related Conditions & MeSH terms

• Age-Related Sarcopenia
• Frailty
• Sarcopenia

Intervention

Dietary Supplement:
• Prebiotic food supplement
Darmocare Pre = trade name Gut microbiome modulator
• Protein supplement
commercially available protein supplementation with high leucine content
• Maltrodextrin (placebo)
Starchy substance

Locations

Country	Name	City	State
United Kingdom	Department of Twin Research and Genetics	London

Sponsors (2)

Lead Sponsor	Collaborator
King's College London	Co-sponsor: Guy's and St Thomas' NHS Foundation Trust

Country where clinical trial is conducted

United Kingdom, 

References & Publications (1)

Ni Lochlainn M, Bowyer RCE, Steves CJ. Dietary Protein and Muscle in Aging People: The Potential Role of the Gut Microbiome. Nutrients. 2018 Jul 20;10(7). pii: E929. doi: 10.3390/nu10070929. Review. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in chair rise time	Chair rise time refers to the time it takes to complete 5 chair rises, without using arms. It is a well-recognised proxy marker of muscle strength. The change from baseline chair rise time at 12 weeks is the primary outcome. The residuals of change will be used in analysis.	baseline and end of study (12 weeks)
Secondary	Gripstrength, as measured by dynamometer	A marker of muscle strength, measured in kilograms. Dominant hand will be used. (absolute and change from baseline at 12 weeks)	baseline and end of study (12 weeks)
Secondary	Microbiome composition	faecal samples analysed for their microbial composition, aka the presence of bacteria in the stool. The bacteria present will be identified where possible and quantified. The diversity of the microbiota present will be calculated using standard protocols. (absolute and change from baseline at 12 weeks)	baseline and end of study (12 weeks)
Secondary	Metabolites in serum	Serum samples analysed for their metabolite composition, aka the presence of metabolites in the blood. Those present will be identified where possible and quantified. (absolute and change from baseline at 12 weeks)	baseline and end of study (12 weeks)
Secondary	Cognition	CANTAB Battery. (absolute and change from baseline at 12 weeks)	baseline and end of study (12 weeks)
Secondary	Questionnaire measures: appetite as measured by SNAQ	SNAQ: Simplified Nutritional Appetite Questionnaire (absolute and change from baseline at 12 weeks)	baseline and end of study (12 weeks)
Secondary	Questionnaire measures: physical activity as measured by IPAQ	IPAQ: international physical activity questionnaire. (absolute and change from baseline at 12 weeks)	baseline and end of study (12 weeks)
Secondary	Salivary microbiome	saliva samples analysed for their microbial composition, aka the presence of bacteria in the saliva. The bacteria present will be identified where possible and quantified. The diversity of the microbiota present will be calculated using standard protocols. (absolute and change from baseline at 12 weeks)	baseline and end of study (12 weeks)
Secondary	Urinary microbiome	Urine samples analysed for their microbial composition, aka the presence of bacteria in the urine. The bacteria present will be identified where possible and quantified. The diversity of the microbiota present will be calculated using standard protocols. (absolute and change from baseline at 12 weeks)	baseline and end of study (12 weeks)
Secondary	Anthropological measures: height	height, measured in centimetres. (absolute and change from baseline at 12 weeks)	baseline and end of study (12 weeks)
Secondary	Anthropological measures: weight	measured in kilograms. (absolute and change from baseline at 12 weeks)	baseline and end of study (12 weeks)